

Mometasone Suspension Formulation

Version 6.1 Revision Date: 26.09.2023 SDS Number: 23610-00022 Date of last issue: 20.03.2023
Date of first issue: 21.10.2014

Section 1: Identification

Product name : Mometasone Suspension Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Hazardous to the aquatic environment - chronic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal word : None

Hazard statements : H411 Toxic to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P273 Avoid release to the environment.

Response:

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Mometasone Suspension Formulation

Version 6.1 Revision Date: 26.09.2023 SDS Number: 23610-00022 Date of last issue: 20.03.2023
Date of first issue: 21.10.2014

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Glycerine	56-81-5	>= 1 -< 10
Cellulose	9004-34-6	>= 1 -< 10
Mometasone	83919-23-7	>= 0.025 -< 0.1
Benzalkonium chloride	8001-54-5	>= 0.0025 -< 0.025

Section 4: First-aid measures

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment : Wear self-contained breathing apparatus for firefighting if nec-

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

for firefighters : necessary.
 Use personal protective equipment.
 Hazchem Code : 3Z

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
 Prevent further leakage or spillage if safe to do so.
 Prevent spreading over a wide area (e.g. by containment or oil barriers).
 Retain and dispose of contaminated wash water.
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
 For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
 Clean up remaining materials from spill with suitable absorbent.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Mometasone Suspension Formulation

Version 6.1 Revision Date: 26.09.2023 SDS Number: 23610-00022 Date of last issue: 20.03.2023
Date of first issue: 21.10.2014

Materials to avoid : Store in accordance with the particular national regulations.
: Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	WES-TWA (Mist)	10 mg/m ³	NZ OEL
Cellulose	9004-34-6	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Section 9: Physical and chemical properties

Appearance	:	liquid
Colour	:	white to off-white, opaque
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	4.3 - 4.9
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm ³
Solubility(ies) Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Glycerine:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Benzalkonium chloride:

Acute oral toxicity : LD50 (Rat): 240 mg/kg

Acute inhalation toxicity : LC50 (Rat, male): > 0.05 - 0.5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: Corrosive to the respiratory tract.
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat, female): 704 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Glycerine:**

Species : Rabbit
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Benzalkonium chloride:

Species : Human
Result : Corrosive after 4 hours or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Glycerine:**

Species : Rabbit

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Result : No eye irritation

Mometasone:

Species : Rabbit
Result : No eye irritation

Benzalkonium chloride:

Species : Rabbit
Result : Irreversible effects on the eye

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Mometasone:**

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Benzalkonium chloride:

Test Type : Human repeat insult patch test (HRIPT)
Exposure routes : Skin contact
Species : Humans
Result : negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Glycerine:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Benzalkonium chloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Glycerine:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Mometasone Suspension Formulation

Version 6.1 Revision Date: 26.09.2023 SDS Number: 23610-00022 Date of last issue: 20.03.2023
Date of first issue: 21.10.2014

Dose : 0.160 mg/kg body weight
Result : negative

Benzalkonium chloride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Skin contact
Exposure time : 80 weeks
Result : negative

Species : Rabbit
Application Route : Skin contact
Exposure time : 90 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

- Species: Rat
 Application Route: Subcutaneous
 Fertility: NOAEL: 0.015 mg/kg body weight
 Symptoms: Reduced embryonic survival, Reduced foetal weight
 Result: No effects on fertility, Effect on reproduction capacity
- Effects on foetal development : Test Type: Embryo-foetal development
 Species: Mouse
 Application Route: Subcutaneous
 Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
 Result: Embryotoxic effects., Teratogenicity and developmental toxicity
- Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
 Result: Embryo-foetal toxicity
- Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.
- Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Subcutaneous
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
 Result: Effects on newborn
- Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.
- Benzalkonium chloride:**
- Effects on fertility : Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 416
 Result: negative
 Remarks: Based on data from similar materials
- Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rabbit

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Application Route: Ingestion
 Method: OECD Test Guideline 414
 Result: negative
 Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Exposure routes : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Benzalkonium chloride:

Assessment : No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

Repeated dose toxicity**Components:****Glycerine:**

Species : Rat
 NOAEL : 0.167 mg/l
 LOAEL : 0.622 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 13 Weeks

Species : Rat
 NOAEL : 8,000 - 10,000 mg/kg
 Application Route : Ingestion
 Exposure time : 2 yr

Species : Rabbit
 NOAEL : 5,040 mg/kg
 Application Route : Skin contact
 Exposure time : 45 Weeks

Cellulose:

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Species : Rat
 NOAEL : $\geq 9,000$ mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Mometasone:

Species : Rat
 NOAEL : 0.005 mg/kg
 LOAEL : 0.3 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
 LOAEL : 0.5 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
 NOAEL : 0.00013 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 90 d
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog
 NOAEL : 0.0005 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 90 d
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Benzalkonium chloride:

Species : Rat
 NOAEL : ≥ 100 mg/kg
 Application Route : Ingestion
 Exposure time : 12 Weeks

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Experience with human exposure**Components:****Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks : Dermal absorption possible

Section 12: Ecological information**Ecotoxicity****Components:****Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Benzalkonium chloride:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 0.28 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.0056 mg/l
 Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Chlorella pyrenoidosa (algae)): 0.09 mg/l
 Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 100

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.032 mg/l
 Exposure time: 34 d

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Persistence and degradability**Components:****Glycerine:**

Biodegradability : Result: Readily biodegradable.
 Biodegradation: 92 %
 Exposure time: 30 d
 Method: OECD Test Guideline 301D

Cellulose:

Biodegradability : Result: Readily biodegradable.

Mometasone:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 50 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
 Method: OECD Test Guideline 111

Benzalkonium chloride:

Biodegradability : Result: Readily biodegradable.
 Method: OECD Test Guideline 301D
 Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.75

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
 Bioconcentration factor (BCF): 107.1
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Benzalkonium chloride:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
 Bioconcentration factor (BCF): < 500
 Remarks: Based on data from similar materials

Partition coefficient: n-octanol/water : log Pow: 1.692
 Remarks: Calculation

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Mometasone, Benzalkonium chloride)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Mometasone, Benzalkonium chloride)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Mometasone, Benzalkonium chloride)

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Benzalkonium chloride)

Class	: 9
Packing group	: III
Labels	: 9
Hazchem Code	: 3Z
Marine pollutant	: no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

Section 16: Other information

Revision Date	: 26.09.2023
---------------	--------------

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

SAFETY DATA SHEET



Mometasone Suspension Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
6.1	26.09.2023	23610-00022	Date of first issue: 21.10.2014

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN